Afya (NasdaqGS:AFYA) Stock Looks Cheap As Digital Growth Misfires

Afya’s stock ticked up about 3% today, a modest move for a company that just told investors it is leaning harder into growth investments while still printing healthy profits. The market’s first instinct looks cautious rather than euphoric. Yet the headline is clear. Afya is running a profitable medical education and healthtech platform with trailing earnings that imply a P/E of roughly 8x and a net margin near 20%, while management leans into an investment cycle that is shaving some cushion off EBITDA margins.

Is Afya a straightforward value opportunity at about 8x trailing earnings, or is the discount a signal that the market is bracing for slower growth ahead? See how current assumptions, peer comparisons and cash flow expectations line up in our valuation analysis for Afya

Q2 2026 Earnings Summary

• Total Revenue, TTM Q2 2026 vs. TTM Q2 2025: BRL 3,773.607m vs. BRL 3,545.960m (up about 6.4%)
• Net Income from Continuing Operations, TTM Q2 2026 vs. TTM Q2 2025: BRL 773.170m vs. BRL 711.999m (up about 8.6%)
• Basic EPS, TTM Q2 2026 vs. TTM Q2 2025: BRL 8.3932 vs. BRL 7.686986 (up about 9.2%)
• Net Profit Margin, TTM Q2 2026 vs. TTM Q2 2025: 20.1% vs. 19.8% (slight margin expansion)

Prefer interactive charts instead of another dense block of earnings figures and margin tables? See Afya’s full financial picture with a clear visual view of its valuation in our company report for Afya.

Afya’s Growth Story Meets Mixed Execution Milestones

Bulls argue Afya can turn medical education scale and healthtech into a higher margin, more diversified platform. Recent numbers show that core education is largely doing its part. Undergrad revenue reached BRL 1,762m with medical seats up 6%, students up 3% and net average ticket up 4%. Net income from continuing operations on a TTM basis also moved ahead and net margin stayed around 20%, which supports the idea that the current investment cycle is being funded from a solid base.

The tougher test of the bullish narrative sits in digital. Continued education students grew 23%, yet revenue in that segment rose only 5%, which signals mix moving to lower ticket courses rather than clear high margin traction. Medical practice solutions revenue rose 2% with flat active payers and pressure at Whitebook. That falls short of the “rapid digital penetration” that the thesis needs over time.

Compare Afya’s 20% net margin and growing education base with how institutions are actually framing the stock. See whether the recent 3.2% move in the share price lines up with analyst conviction by checking the consensus price target analysis for Afya.

Afya Bear Case: Growth Optionality Still Under Question

The bearish view argues Afya’s campus model faces structural pressure from AI driven and online medical training, with limited offset from digital and continuing education. The latest results give that concern some traction. Core undergraduate metrics look solid, yet the key hedge against disruption, the digital ecosystem, is not firing on all cylinders. Continued education students grew strongly but revenue rose only 5%, which confirms a mix shift to lower ticket courses rather than clear pricing power. Medical practice solutions revenue grew 2% with flat active payers and monthly active users down 8%, while Whitebook is already seeing churn and required price cuts in response to AI competitors.

Margins compressed by 190 bps as Afya stepped up product and AI spend, so investors are paying for defense against disruption without yet seeing broad based digital monetization. That is a milestone missed for anyone looking to disprove the structural bear case.

After Afya’s digital churn, pricing pressure and heavier AI spend, are these setbacks isolated or early signs of deeper structural issues? Review our risk analysis for Afya which shows 1 important warning sign

Take Control Of Your Next Move

If Afya’s mix of solid profitability and open questions around digital growth has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the thesis develops. Once you decide to take a position, keep your focus with the Portfolio Command Center that cuts through noise and highlights only the most important changes to your holdings. For a broader view on Afya and other stocks, use the Community to see how different investors are thinking about the same risks and opportunities. That way you spot potential catalysts or warning signs earlier and stay a step ahead of the market.

Seeking Fresh Alternatives Beyond Afya?

Some of the most interesting stocks often move from quiet to breakout before most investors react. Check these curated ideas while they are still under the radar for now and get in early.

• Spot companies building steady momentum in quality and balance sheet strength, then size up a curated list of solid balance sheet and fundamentals stocks (50 results) before the crowd catches on and prices start flying.
• Hunt for income opportunities that aim to keep cash flows coming in, and scan a focused group of 10 dividend fortresses while yields still look compelling and risks are clearly laid out.
• Track the picks where profitable AI meets discipline, and review a filtered set of 76 profitable AI stocks that aren't just burning cash before valuations get caught up by late money chasing the trend.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com